## PAR DRUGS AND CHEMICALS LIMITED (CIN: L24117GJ1999PLC035512)

# Registered Office: 805, Dwarkesh Complex, R C Dutt Road, Alkapuri, Vadodara (Gujarat) Audited Financial Results for the Half Year Ended 31st March, 2020 Statement Of Assets And Liabilities

Rs. In Lakhs

				NS. III LANIIS
	Particulars	AS AT	AS AT	
	raiticulais		31.03.2020	31.03.2019
			Audited	Audited
I.	EQUITY AND LIABILITIES			
1	Shareholders' funds			
	(a) Share capital		615.23	448.03
	(b) Reserves and surplus		3,446.22	2,454.86
	(c) Money received against share warrants		0.00	0.00
	Sub-total (1)		4,061.45	2,902.89
2	Share application money pending allotment		0.00	0.00
	Non-current liabilities		0.00	0.00
٦	(a) Long-term borrowings		461.91	603.14
	(b) Deferred tax liabilities (Net)		365.12	342.43
	(c) Other Long term liabilities		0.00	0.00
	(d) Long-term provisions		38.62	32.69
	Sub-total (2)		865.65	978.27
4	Current liabilities			ا ب م ب م ب
	(a) Short-term borrowings		0.00	431.91
	(b) Trade payables			
	Due to Micro, Small & Medium Enterprise		0.00	0.00
	Due to Others		620.46	493.18
	(c) Other current liabilities		269.10	233.15
	(d) Short-term provisions		194.85	87.32
	Sub-total (3)		1,084.42	1,245.57
		TOTAL	6,011.52	5,126.73
II.	ASSETS			
	Non-current assets			
1	(a) Property, Plant and Equipment			
	(i) Tangible assets		3,439.62	3,634.10
	(ii) Intangible assets		0.00	0.00
	(iii) Capital work-in-progress		73.90	0.00
	(iv) Intangible assets under development		0.00	0.00
	( ) 3		3,513.52	3,634.10
	(b) Non-current investments		5.65	5.65
	(c) Deferred tax assets (net)		0.00	0.00
	(d) Long-term loans and advances		70.50	68.58
	(e) Other non-current assets		0.00	0.00
	Sub-total (1)		3,589.67	3,708.33
2	Current assets		0,000.01	0,1 00.00
	(a) Current investments		0.00	0.00
	(b) Inventories		291.68	429.41
	(0)		1,236.84	851.97
	(c) Trade receivables (d) Cash and cash equivalents		737.92	3.06
	(e) Short-term loans and advances		737.92 62.27	61.05
			93.14	
	( )			72.92
	Sub-total (2)	TOTAL	2,421.85	1,418.40
1		TOTAL	6,011.52	5,126.73

Savani Jignesh Vallabhbhai

Digitally signed by Savani Jignesh Vallabhbhai Dik c-Hk, o-Piersonal, cn-Savani Jignesh Vallabhbhai Dik c-Hk, o-Piersonal, cn-Savani Jignesh Vallabhbhai Vallabhbh

For and on behalf of Board of Directors Par Drugs and Chemicals Limited

FALGUN VALLABHBHAI SAVANI

Jigneshbhai V Savani (CEO) (DIN - 00198203) Bhavnagar, 1st June, 2020 Falgun V Savani (Managing Director) (DIN - 00198236) Bhavnagar, 1st June, 2020

#### PAR DRUGS AND CHEMICALS LIMITED (CIN: L24117GJ1999PLC035512)

Registered Office: 805, Dwarkesh Complex, R C Dutt Road, Alkapuri, Vadodara (Gujarat) Audited Financial Results for the Half Year Ended 31st March, 2020 Statement Of Profit & Loss

Rs. In Lakhs

Particulars		Half Year Ended			Year Ended	
		31.03.2020	30.09.2019	31.03.2019	31.03.2020	31.03.2019
		Audited	Unaudited	Unaudited	Audited	Audited
I.	Revenue from operations	2,673.73	2,911.14	2,146.17	5,584.87	4,632.33
II.	Other income	9.68	0.17	8.87	9.86	8.87
III.	Total Revenue (I + II)	2,683.41	2,911.32	2,155.04	5,594.72	4,641.20
IV.	Expenses:					
	Cost of materials consumed	1,070.34	1,148.78	889.83	2,219.12	1,922.04
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods work-in-	63.18	83.27	-49.02	146.45	0.11
	progress and Stock-in-Trade					
	Employee benefits expense	207.37	203.99	158.32	411.36	363.91
	Finance costs	37.48	41.91	82.27	79.39	196.30
	Depreciation and amortization expense	6.60	269.55	171.11	276.15	303.70
	Other expenses Total expenses (IV)	909.75 <b>2,294.71</b>	953.32 <b>2,700.83</b>	782.71 <b>2,035.21</b>	1,863.06 <b>4,995.54</b>	1,525.98 <b>4,312.04</b>
	Total expenses (IV)	2,294.71	2,700.83	2,035.21	4,995.54	4,312.04
V.	Profit before exceptional and extraordinary items	388.70	210.49	119.83	599.19	329.17
٧.	and tax (III-IV)	300.70	210.49	119.03	599.19	329.17
VI.	Exceptional items	0.00	0.00	0.00	0.00	0.00
VII.	Profit before extraordinary items and tax (V - VI)	388.70	210.49	119.83	599.19	329.17
•	trong poroto extraoramany normo ama tax (t = tr,	000.70	210.40	110.00	000.10	020.17
VIII.	Extraordinary Items	0.00	0.00	0.00	0.00	0.00
IX.	Profit before tax (VII- VIII)	388.70	210.49	119.83	599.19	329.17
Χ	Tax expense:					
	(1) Current tax	56.70	43.30	67.80	100.00	67.80
	(2) Deferred tax	14.37	8.32	10.26	22.69	10.26
ΧI	Profit (Loss) for the period from continuing	317.63	158.86	41.77	476.50	251.10
	operations (VII-VIII)					
XII	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
XIII	Tax expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00
χV	Profit (Loss) for the period (XI + XIV)	317.63	158.86	41.77	476.50	251.10
XVI	Earnings per equity share:	211100			11 2.00	
	(1) Basic.	5.16	2.58	0.93	7.75	5.60
	(2) Diluted.	5.16	2.58	0.93	7.75	5.60

Savani **Jignesh** Vallabhbhai

Jigneshbhai V Savani (CEO) (DIN - 00198203) Bhavnagar, 1st June, 2020

For and on behalf of Board of Directors

Par Drugs and Chemicals Limited AVANI FALGUN VALLABHBHAI

SAVANI

Falgun V Savani (Managing Director) (DIN - 00198236) Bhavnagar, 1st June, 2020

## PAR DRUGS AND CHEMICALS LIMITED (CIN: L24117GJ1999PLC035512)

Registered Office: 805, Dwarkesh Complex, R C Dutt Road, Alkapuri, Vadodara (Gujarat)
Audited Financial Results for the Half Year Ended 31st March, 2020
Statement of Cash Flow

Rs. In Lakhs

E				Rs. In Lakhs
Particulars				Ended
	31.03.2020	30.09.2019	31.03.2020	31.03.2019
A: CASH FLOW FROM OPERATING ACTIVITIES:	Audited	Unaudited	Audited	Audited
	388.70	210.49	599.19	329.17
Net profit before tax as per P & L Statement.	388.70	210.49	599.19	329.17
Adjusted for: Depreciation	6.60	269.55	276.15	303.70
Income-tax/Prior Year Adjustment	0.00	-1.04	-1.04	-44.61
Interest Expense	61.76	13.64		181.15
Rent, Interest & Dividend Income	-7.47	-0.17	-7.65	-8.87
Profit/Loss on sale of assets	-2.21	0.00		0.00
	58.68	281.98		431.37
	447.38	492.47	939.85	760.54
Operating Profit /(loss) before working capital changes				
Adjustments for changes in working capital				
Adjustments for (increase)/decrease in operating assets				
Long Term Loans & Advances	8.24	-10.17	-1.92	1.00
Inventories	21.67	116.06	137.73	-22.66
Trade Receivables.	5.29	-390.15	-384.86	20.49
Short Term Loans & Advances	8.83	-10.06	_	7.80
Other Current Assets	-3.48	0.72	-2.76	0.34
Adjustments for increase/(decrease) in operating liabilities				
Long-term provisions	5.93	0.00		32.69
Short-term provisions	-7.00	5.43		19.52
Other Current Liabilities	68.42	-32.48		-379.81
Trade Payables	-75.05 <b>32.86</b>	202.33 -118.32		-32.95 <b>-353.58</b>
	32.00	-110.32	-05.40	-353.56
Cash Generated from / (used in) Operating activities	480.24	374.14	854.39	406.95
Less: Income-Tax paid	-42.29	-42.97	-85.27	-71.02
	437.95	331.17	769.12	335.93
Net Cash genereated from / (used in) Operating Activities:				
B: CASH FLOW FROM INVESTING ACTIVITIES:				
Purchase of Fixed Assets	-137.03	-18.84	-155.87	-34.30
Sales of Fixed Assets	2.50	0.00	2.50	0.00
Rent, Interest & Dividend Income	7.47	0.00	7.65	8.87
rioni, morosi a Britana morno		0	1.00	0.01
Net Cash generated from / (used in) Investing Activities:	-127.06	-18.66	-145.72	-25.43
C: CASH FLOW FROM FINANCING ACTIVITIES:				
Proceeds from Issue of Shares	0.00	852.72	852.72	600.00
Proceeds from Long Term Borrowings	0.00	0.00		
Repayment of Long Term Borrowings	-148.47	7.24		
Repayment of Short Term Borrowings	0.00	-431.91	-431.91	-76.34
Dividend Paid	-75.41	0.00		-181.15
Dividend Tax paid	0.00	0.00	-	
Interest paid	13.64	-13.64		0.00
	-302.95	414.41	111.46	-313.82
Net Cash generated from / (used in) Financing Activities:	-302.95	414.41	111.40	-313.62
Net Increase ((Decrease) in Oast and Oast East	= 6 1	200.00	70100	
Net Increase/(Decrease) in Cash and Cash Equivalents	<b>7.94</b> 729.97	<b>726.92</b>	<b>734.86</b>	-3.32
Opening Balance of Cash and Cash Equivalents	729.97	3.06	3.06	6.38
Closing Balance of Cash and Cash Equivalents	737.92	729.97	737.92	3.06
Total:	7.94	726.92	734.86	-3.32

- 1. Purchase of fixed assets are stated inclusive of movement of Capital Work in Progress and advance for capital goods between the commencement and end of the year and are considered as part of investing activity.
- 2. The cash flow statement has been prepared under the "indirect method" as set out in Accounting Standard 3 on Cash Flow Statement issued by the Institute of Chartered Accountants of India.

Savani Jignesh Vallabhbhai

Digitally signed by Series I Signed h Vladishhad.

Dit cells, or Personal, cent Series I Igned h Vladishhad.

Dit cells, or Personal, cent Series I Igned h Vladishhad.

Dit cells, or Personal, cent Series I Igned h Vladishhad.

Dit cells of Series I Igned h Vladishhad.

Dit cells of Series I Igned h Vladishhad.

Dit cells of Series I Igned h Vladish Igned h Vladish Igned horizon I Igned h Vladish Igned h Vladis

Jigneshbhai V Savani (CEO) (DIN - 00198203) Bhavnagar, 1st June, 2020 For and on behalf of Board of Directors
Par Drugs and Chemicals Limited
FALGUN
VALLABHBHAI

Falgun V Savani (Managing Director) (DIN - 00198236) Bhavnagar, 1st June, 2020

SAVANI

### PAR DRUGS AND CHEMICALS LIMITED

#### **NOTES:**

- 1. Above audited financial results have been reviewed by audit committee in their meeting held on 30th May, 2020 and approved by the Board of Directors in their meeting held on 1st June, 2020
- 2. The Auditor of the company have carried out a audit of the financial results for the half year and year ended 31st March, 2020 in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015 and have expressed their unqualified opinion.
- 3. Figures for the half year ended 31st March, 2020 are balancing figures between audited figures in respect of full financial year and the published year to date figures of the first half year. The figures up to the end of the half year ended 30th September, 2019 were subject to limited review.
- 4. Previous year / period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures.
- 5. The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Accounting Standard 17 on Segment Reporting. Accordingly, there are no other business segments to be reported under Accounting Standard 17.
- 6. The Company does not have any subsidiary, associates or joint venture as on 31st March, 2020; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company.
- 7. The Bank Balance is included in Cash and Cash Equivalents of the Company.
- 8. The above financials are available on the Company's website www.pardrugs.com.
- 9. The Status of investors complaints received by the Company are as follows:
  - Ι. Received during the period from 1st October, 2019 to 31st March, 2020: NIL
  - II. Disposed during the period from 1st October, 2019 to 31st March, 2020: NIL
  - Pending as on 31st March, 2020: NIL III.

For and on behalf of Board of Directors

Par Drugs and Chemicals Limited

**FALGUN** 

Digitally signed by FALGUN VALLABHBHAI SAVANI
DN: c=IN, o=Personal, postalCode=391410, st=Gujarat, 

Falgun V Savani (Managing Director) (DIN - 00198236)

Savani Jignesh

Digitally signed by Savani Jignesh Vallabhbhai DN: c=lN, o=Personal, cn=Savani Jignesh Vallabhbhai, serialNumber=7cd01728a9e077d3e3795bafa1bb1 c7a06bcab06e12dbb644fe8fafee55c7ef, pseudonym=107r23efdaa94d5fbb4b2c756c63858

25.4.45-09.4100653365306631653139053833343 Vallabhbhai 25.4.20-08.41006533653066313333503467550 26.6213832735616.63, postalcode-9540010, 2.5.4.20-08.add.85.e50(0.6d77110916e0)2a1ffd/5f67 9992b01816560130172-86f2467, st-Gujarat Date: 2020.0601183131+0530

Jigneshbhai V Savani (CEO) (DIN - 00198203)

Bhavnagar, 1st June, 2020



**Registered Office:** 805, Dwarkesh Complex, R. C. Dutt Road, Alkapuri, Vadodara – 390 007. Gujarat (INDIA). | **Ph.** : +91-265-2342018 / 2332018 | **Fax** : +91-265-2332018

Corporate Office: 302, Anmol Plaza, Waghawadi Road, Bhavnagar. | Ph.: +91-278-2447013

Email: admin@pardrugs.com

CIN No.: L24117GJ1999PLC035512

www.pardrugs.com

To,
The Board of Directors
Par Drugs And Chemicals Limited

## **CERTIFICATE OF CORRECTNESS OF FINANCIAL RESULTS**

Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby certify that the financial results of the Company for the half year & year ended 31<sup>st</sup> March, 2020 placed before the meeting the financial results do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

For Par Drugs And Chemicals Limited

(Mr. Jignesh V. Savani) Chief Executive Officer Date: 01/06/2020

Place: Bhavnagar

For Par Drugs And Chemicals Limited

(Mr. Chintan P. Chauhan) Chief Financial Officer





Registered Office: 805, Dwarkesh Complex, R. C. Dutt Road, Alkapuri, Vadodara - 390 007. Gujarat (INDIA). | Ph. :+91-265-2342018 / 2332018 | Fax:+91-265-2332018

Corporate Office: 302, Anmol Plaza, Waqhawadi Road, Bhavnagar. | Ph.: +91-278-2447013

Email: admin@pardrugs.com

CIN No.: L24117GJ1999PLC035512

www.pardrugs.com

Date:01-06-2020

To,

The Manager

Listing department,

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block-G,

Bandra Kurla Complex, Bandra (E),

Mumbai- 400 051

Maharashtra

Subject: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and

Disclosure Requirements), Regulations 2015

Ref.: Symbol- PAR (NSE Emerge), ISIN: INE04LG01015

Dear Sir/Madam,

I, Chintan P. Chauhan, Chief Financial Officer of Par Drugs And Chemicals Limited hereby declare that the Statutory Auditors of the Company, M/s V Dhamsania & Associates, Chartered Accountants, having FRN 132499W, Partnership Firm has issued an Audit Report with unmodified opinion on Audited Standalone Financial Results of the Company for the financial year ended March 31, 2020.

This declaration is given pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 and Circular No. CIR/CFD/CMD/56/ 2016 dated May 27, 2016.

Kindly take on the record and acknowledge the receipt

Yours Faithfully

For PAR DRUGS AND CHEMICALS LIMITED

(Chintan P. Chauhan)

**Chief Financial Officer**